secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2026-06-22T12:01:50+00:00
Accession:  0001104659-26-076091
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Definium Therapeutics reports positive Phase 3 results for DT120 ODT in major depressive disorder
--------------------------------------------------------------------------------

- Study met primary endpoint with 8.1-point MADRS placebo-adjusted improvement at Week 6 (p<0.0001)
- 7.3-point MADRS placebo-adjusted improvement at Week 12 (p<0.0001), showing durability
- DT120 ODT was generally well tolerated; no serious adverse events or suicidality signal
- Company to host webcast at 8:00 a.m. EDT on June 22, 2026 to discuss results

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000110465926076091/0001104659-26-076091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000110465926076091/tm2618434d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-076091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer